Corning led a bioprocessing and CDMO pullback, off 6.4%, as AI-optics crosscurrents and China-exposure weighed on the group; primary-packaging name Aptar (+1.1%) was the rare gainer.

AptarGroup (ATR) was the rare clean gainer in the pharma-supply vertical, up 1.1% to $121.81. The broader basket was red on the same risk-off tape that defined the session — a Financial Times report that OpenAI's annualized revenue was running near $50bn, below the roughly $70bn expected, cracked the AI trade, and yields and oil rose — but the drawdown was milder here than in the AI-levered sectors, because this vertical's chokepoints (primary packaging, fill-finish, bioprocessing) are defensive. Aptar, on the drug-delivery and primary-packaging rung (injectable and inhalation dispensing systems), led, with Amphastar Pharmaceuticals (AMPH) also up 1.1% to $25.81.

The laggard was Corning (GLW), down 6.4% to $152.83. Corning straddles two of this basket's themes — pharmaceutical glass (its Valor vials, the primary-packaging chokepoint) and, far larger in revenue, optical fiber for datacenters — so it was caught in the same AI-optics selloff that hammered the compute vertical, which dragged the pharma line with it. The move was a read on the AI/optical complex, not on pharmaceutical-packaging demand.

The China-exposed CDMO and bioprocessing rung — squarely in the BIOSECURE Act's crosshairs — sold: WuXi Biologics (WXIBF) −4.3% to $7.17 and WuXi AppTec (WUXAY) −4.2% to $26.83. The Western bioprocessing names were soft in sympathy: Fresenius (FSNUY) −3.9%, Sartorius (SOAGY) −3.7%, Maravai LifeSciences (MRVI) −3.0% to $7.21, and Repligen (RGEN) −2.0% to $163.84. The analytical-instruments and tools rung held up better: Thermo Fisher (TMO) −1.5% to $651.98 and Waters (WAT) −1.6% to $429.13. Eli Lilly (LLY) eased 1.6% to $1,169.60.

The next catalysts split between earnings and policy. West Pharmaceutical reports Q3 around Oct 22 and Charles River around Nov 5 (both estimated) — the cleanest reads on fill-finish and preclinical-services demand. The hard policy date is Dec 18, when the BIOSECURE Act's OMB "biotechnology companies of concern" initial list is statutorily due — the catalyst that could formalize the China-CDMO chokepoint the WuXi names were pricing today.